Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A nested case-control study on mortality in users of ibopamine

B H Stricker1, J Feenstra, J P Ottervanger

  • 1Drug Safety Unit, Inspectorate for Health Care, Rijswijk, Netherlands.

The Netherlands Journal of Medicine
|February 10, 1998
PubMed
Summary

Ibopamine treatment in heart failure patients showed increased mortality risk, particularly in those with NYHA class IV and high serum creatinine. Higher ibopamine doses appeared protective, but amiodarone use was more frequent in deceased patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are higher antidepressant plasma concentrations associated with fall risk in older antidepressant users?

European geriatric medicine·2023
Same author

Resting heart rate and incident atrial fibrillation: A stratified Mendelian randomization in the AFGen consortium.

PloS one·2022
Same author

Candidate genetic variants and antidepressant-related fall risk in middle-aged and older adults.

PloS one·2022
Same author

Appendectomy and the subsequent risk of cancer: A prospective population-based cohort study with long follow-up.

Cancer epidemiology·2022
Same author

A Propensity Score Matched Approach to Assess the Associations of Commonly Prescribed Medications with Fall Risk in a Large Harmonized Cohort of Older Ambulatory Persons.

Drugs & aging·2021
Same author

Prevalence of and risk factors for extended-spectrum beta-lactamase genes carriership in a population-based cohort of middle-aged and elderly.

International journal of antimicrobial agents·2021

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Interim analysis of the PRIME II study indicated higher mortality with ibopamine compared to placebo.
  • Need to investigate ibopamine-related mortality and identify associated risk factors.

Purpose of the Study:

  • To evaluate mortality rates in patients treated with ibopamine.
  • To identify independent risk factors contributing to death in this patient cohort.

Main Methods:

  • A follow-up study with a nested case-control design was employed.
  • Data collected from 3148 ibopamine users via drug-dispensing outlets and general practitioner inquiries.
  • Risk factors assessed included NYHA classification, serum creatinine, and concomitant medications.

Related Experiment Videos

Main Results:

  • Overall mortality in the studied ibopamine users was 25%.
  • NYHA class IV and highest quartile serum creatinine levels were associated with a threefold increased risk of death.
  • Higher ibopamine doses suggested a protective effect; amiodarone and opioid use were more common in deceased patients.

Conclusions:

  • NYHA classification and serum creatinine levels are independent risk factors for mortality in heart failure patients on ibopamine.
  • Increased risk estimates for ibopamine and amiodarone use did not reach statistical significance, potentially due to sample size limitations.